An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer

CompletadoFase 2ClinicalTrials.gov

ID: NCT01677455Tipo: INTERVENTIONALInicio: 1 de jul de 2012Fin estimado: 1 de ago de 2015

Oncología Endocrinología Obstetricia y Ginecología

Traducción no disponible, mostrando original

Resumen

The purpose of this study is to determine if ganetespib (STA-9090) is effective in the treatment of patients with HER2+ or triple negative breast cancer who have not received prior systemic treatment in the metastatic setting.

Elegibilidad

Edad mínima: 18 YearsSexo: FEMALE

Criterios de inclusión

Pathologically confirmed diagnosis of invasive breast cancer.
Stage IV disease.
Documented HER2 and hormonal receptor status per protocol, ER/PR+ patients must be refractory to at least one prior hormonal treatment.
ECOG Performance status 0-1.
Measurable disease per RECIST (1.1).
Adequate hematological function per protocol.
Adequate hepatic function per protocol.
Adequate renal function per protocol.
Negative serum pregnancy test at study entry for patients of childbearing potential.
Ability to understand and sign written consent and to comply with the study protocol.

Criterios de exclusión

Presence of active or untreated CNS metastases as determined by MRI/CT scan performed during screening.
Active malignancies other than MBC within the last 5 years except adequately treated in situ carcinoma of the cervix uteri or basal or squamous cell carcinoma of the skin.
Bone as the only site of metastatic disease from breast cancer.
Prior radiotherapy to the only area of measurable disease. NOTE: Radiotherapy to a limited area other than the sole site of measurable disease is allowed, if received prior to initiation of ganetespib treatment. Patients must have completed treatment and recovered from all acute treatment-related toxicities prior to administration of first dose of ganetespib.
Pregnancy or lactation.
Known serious cardiac illness.
Uncontrolled intercurrent illness per protocol.
Other severe acute or chronic medical condition or abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, or that in the judgment of the investigator would make the patient inappropriate for entry into the study.

Intervenciones

drug

ganetespib

Ganetespib 150 mg/m2 will be administered intravenously, twice weekly, for three consecutive weeks of each 4 week cycle.

Ubicaciones

Synta Pharmaceuticals Investigative Site

Córdoba, Argentina

Synta Pharmaceuticals Investigative Site

Rosario Santa Fe, Argentina

Patrocinadores

PrincipalSynta Pharmaceuticals Corp.

Aviso: La información de este ensayo proviene de fuentes públicas y tiene carácter exclusivamente informativo. No constituye asesoramiento médico, regulatorio ni de ningún otro tipo. Las traducciones son automatizadas y no poseen validez oficial. Consultá siempre con un profesional de la salud. Ver Términos de Uso.

An Open-Label Multicenter Phase 2 Window of Opportunity S... | EligiMed